Modality
siRNA
MOA
CDK2i
Target
EGFR
Pathway
Ferroptosis
Breast Ca
Development Pipeline
Preclinical
~Aug 2014
→ ~Nov 2015
Phase 1
~Feb 2016
→ ~May 2017
Phase 2
~Aug 2017
→ ~Nov 2018
Phase 3
~Feb 2019
→ ~May 2020
NDA/BLA
~Aug 2020
→ ~Nov 2021
Approved
Feb 2022
→ Mar 2026
ApprovedCurrent
NCT03672672
550 pts·Breast Ca
2022-02→2026-03·Active
550 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2026-03-231w agoPh3 Readout· Breast Ca
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
Approved
Active
Catalysts
Ph3 Readout
2026-03-23 · 1w ago
Breast Ca
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03672672 | Approved | Breast Ca | Active | 550 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D | |
| REG-2328 | Regeneron | Phase 1 | BCMA |